Karuna Therapeutics Inc

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Karuna Therapeutics reports positive trial results and strong financial outlook

Karuna Therapeutics is making significant progress in its key programs, with positive trial results and a focus on expanding its pipeline. Despite challenges in trial timelines and increased expenses, the company's strong financial position and strategic priorities position it well for future growth.

Karuna Therapeutics reports robust Q2 performance and eyes new indications

Karuna Therapeutics reported strong financials, progress on NDA submission, and ongoing Phase III programs.
The company's focus on cognitive benefits, broader efficacy, and potential new indications showcases strategic growth initiatives.
Challenges include competitive dynamics in Alzheimer's trials and uncertainties in the applicability of KarXT in certain patient populations.
Opportunities lie in exploring new indications, demonstrating cognitive benefits, and enhancing efficacy in mood and anxiety disorders.

Karuna Therapeutics excels in Q3, eyes global expansion for KarXT

Karuna Therapeutics demonstrated strong performance in Q3 with a focus on KarXT Phase III programs and NDA submission, supported by a healthy financial position.
Strategic strengths lie in maximizing KarXT value, positive payer interactions, and broad-based commercial strategies, while challenges include managing expenses and operational considerations.
Opportunities for growth include expanding the TRPC4/5 program, leveraging favorable mental health trends, and pursuing international market partnerships for KarXT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

Karuna Therapeutics: Fundraising Makes For Buying Opportunity

"We're cautiously optimistic given the robustness of the clinical data that we reported this week," Karuna Therapeutics CEO Dr. Steve Paul says.

Karuna Therapeutics 'cautiously optimistic' about schizophrenia drug results in next trial: CEO

History is littered with promising phase 2 drugs that failed upon further testing. Investors shouldn't get caught up in the hype.

Why Investors Should Resist Buying Karuna Therapeutics, Even Though It's Surging

The pharma company announced the pricing of a public stock offering.

Here's Why Karuna Therapeutics Is Tumbling Today

Positive clinical trial results recently sent this stock soaring, but can it climb further?

Is Karuna Therapeutics Stock a Good Buy Now?

Karuna Therapeutics Inc. (NASDAQ: KRTX) shares skyrocketed on Monday after the firm announced mid-stage results from its schizophrenia treatment.

How Karuna Therapeutics Is Capitalizing on Its Game-Changing Schizophrenia Study

Shares of Karuna Therapeutics have septupled in value over two days after the biotech company's schizophrenia treatment succeeded in a midstage test.

Here's Why This Biotech Stock Has Septupled In Value Over Two Days

The great news from a clinical study of experimental schizophrenia drug KarXT still has investors excited about the biotech stock.

Why Karuna Therapeutics Stock Is Soaring Again Today

Peloton

Yandex

Some surprising events lifted these stocks.

Why Peloton Interactive, Yandex, and Karuna Therapeutics Jumped Today

When investors see a stock rise by close to 100%, they probably just assume it’s a corporate buyout.

New Schizophrenia Study May Usher in Game-Changing Standard of Care

Karuna Therapeutics (KRTX) news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock soaring.
The post Karuna Therapeutics News: KRTX Stock Skyrockets 415% on Positive Schizophrenia Trial appeared first on InvestorPlace.

Karuna Therapeutics News: KRTX Stock Skyrockets 415% on Positive Schizophrenia Trial

The clinical-stage biopharmaceutical company announced really great phase 2 results for its lead pipeline candidate.

Why Karuna Therapeutics Stock Is Skyrocketing Today

Shares of Karuna Therapeutics Inc. more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a phase 2 trial of its schizophrenia treatment met its primary endpoint.

Karuna Therapeutics' stock more than triples after upbeat trial results of schizophrenia treatment

Shares of the thinly traded, small-cap biotech Karuna Therapeutics Inc (NASDAQ: KRTX) were moving higher Monday on a positive clinical trial readout.

Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial

AXA Equitable Holdings Inc

Esperion Therapeutics

Liberty Latin America Ltd.

Liberty Latin America

Details the CEO buys this past week for the following companies: AXA Equitable Holdings, Liberty Latin America, Karuna Therapeutics, Esperion Therapeutics and Altus Midstream

Weekly CEO Buys Highlight (July 7)

Coherus BioSciences

DD3 Acquisition Corp - Units (1 Ord & 1 War)

Floor & Decor Holdings

HD Supply Hlds

Motus GI Hlds

OncoCyte

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

Insiders Roundup: OncoCyte, BioSciences

President & CEO of Karuna Therapeutics Inc (NASDAQ:KRTX) Steven M Paul bought 10,000 shares of KRTX on 06/28/2019 at an average price of $23.04 a share.

Karuna Therapeutics Inc (KRTX) President & CEO Steven M Paul Bought $230,400 of Shares

Karuna Therapeutics, Inc. made its public debut Friday morning, opening at $18.50 after being priced at $16 per share.

Karuna Therapeutics Opens Above IPO Price

Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week.

Karuna Therapeutics IPO: What You Need To Know

News for Karuna Therapeutics Inc Stock (KRTX)